Revolution Medicines (RVMD) Expected to Announce Earnings on Wednesday

Revolution Medicines (NASDAQ:RVMD) is projected to issue its Q2 2025 quarterly earnings data after the market closes on Wednesday, August 6th. Analysts expect the company to announce earnings of ($1.14) per share and revenue of $0.50 million for the quarter.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.01). During the same quarter in the prior year, the firm earned ($0.70) EPS. On average, analysts expect Revolution Medicines to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Revolution Medicines Price Performance

Revolution Medicines stock opened at $37.18 on Tuesday. The stock has a market cap of $6.93 billion, a price-to-earnings ratio of -9.30 and a beta of 1.16. Revolution Medicines has a 1 year low of $29.17 and a 1 year high of $62.40. The firm has a 50-day moving average of $38.59 and a two-hundred day moving average of $38.86.

Hedge Funds Weigh In On Revolution Medicines

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Revolution Medicines by 14.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 300,196 shares of the company’s stock valued at $10,615,000 after acquiring an additional 37,345 shares during the period. Millennium Management LLC boosted its holdings in Revolution Medicines by 681.8% during the 1st quarter. Millennium Management LLC now owns 156,353 shares of the company’s stock valued at $5,529,000 after acquiring an additional 136,353 shares during the period. Finally, Nextech Invest Ltd. boosted its holdings in Revolution Medicines by 20.7% during the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock valued at $332,472,000 after acquiring an additional 1,304,347 shares during the period. 94.34% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms recently weighed in on RVMD. HC Wainwright restated a “buy” rating and issued a $72.00 price objective (down from $73.00) on shares of Revolution Medicines in a report on Wednesday, May 14th. Oppenheimer lifted their price objective on Revolution Medicines from $70.00 to $75.00 and gave the company an “outperform” rating in a report on Thursday, May 8th. Guggenheim restated a “buy” rating and issued a $80.00 price objective on shares of Revolution Medicines in a report on Wednesday, June 25th. The Goldman Sachs Group began coverage on Revolution Medicines in a report on Tuesday, July 15th. They issued a “buy” rating and a $65.00 price objective for the company. Finally, Needham & Company LLC restated a “buy” rating and issued a $57.00 price objective on shares of Revolution Medicines in a report on Tuesday, June 24th. Eleven investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $68.91.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.